How AI will transform mental health support for breast cancer patients, narrative review paper details

American College of Radiology approves first ever Practice Parameter for Imaging Artificial Intelligence

The American College of Radiology Council approved the ACR-SIIM (Society for Imaging Informatics in Medicine) Practice Parameter for Imaging Artificial Intelligence at ACR 2026, the College’s annual meeting in Washington, DC.

May 08, 2026

Vol.52 No.18

Clinical Roundup

Mayo Clinic AI detects pancreatic cancer up to three years before diagnosis, validation study finds

A Mayo Clinic has developed an artificial intelligence model that can help specialists detect pancreatic cancer on routine abdominal CT scans up to three years before clinical diagnosis. It identifies subtle signs of disease before tumors are visible, when curative treatment may still be possible.

May 01, 2026

Vol.52 No.17

Drugs & Targets

Unfold AI’s prostate cancer mapping added to regional CMS Physician Fee Schedule

Unfold AI, an AI prostate cancer mapping and clinical decision support platform, is now included in Medicare’s Physician Fee Schedules across the West Coast and Mountain West regions. The regional expansion of Medicare payment for the tool gives urologists and care teams clearer reimbursement pathways in physician office settings, an area that has historically lagged behind hospital outpatient settings for emerging technologies.

May 01, 2026

Vol.52 No.17

In Brief

UT Austin announces first tech-native academic medical center in the U.S.

The University of Texas at Austin is building an integrated academic medical center from the ground up, where care, research, and education operate as one system organized around the patient. This model connects prevention, diagnosis, treatment, and long-term health into a continuous experience, particularly for those with complex and serious conditions.

April 24, 2026

Vol.52 No.16

In Brief

Lisa Eli named chief scientific officer at Zephyr AI

Lisa Eli has been appointed chief scientific officer at Zephyr AI Inc.

April 24, 2026

Vol.52 No.16

Cancer Policy

FDA adds stereotactic breast biopsy needles to the shortage list

FDA has added stereotactic breast biopsy needles to its Medical Device Shortages List with an estimated duration of “through Q4 2026,” which spans July 1 to Sept. 30.

April 17, 2026

Vol.52 No.15

By Jacquelyn Cobb

How AI will transform mental health support for breast cancer patients, narrative review paper details

YOU MAY BE INTERESTED IN

American College of Radiology approves first ever Practice Parameter for Imaging Artificial Intelligence

Mayo Clinic AI detects pancreatic cancer up to three years before diagnosis, validation study finds

Unfold AI’s prostate cancer mapping added to regional CMS Physician Fee Schedule

UT Austin announces first tech-native academic medical center in the U.S.

Lisa Eli named chief scientific officer at Zephyr AI

FDA adds stereotactic breast biopsy needles to the shortage list

Renew today!

Subscriber content

Never miss an issue!

Login